Inhibrx Biosciences, Inc. INBX Fair value of warrants issued to lender in conjunction with 2025 Loan Agreement (as defined in Note 3)
Fair value of warrants issued to lender in conjunction with 2025 Loan Agreement (as defined in Note 3) at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred.
The official record: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s fair value of warrants issued to lender in conjunction with 2025 loan agreement (as defined in note 3).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s fair value of warrants issued to lender in conjunction with 2025 loan agreement (as defined in note 3)?
- Inhibrx Biosciences, Inc. (INBX) reported fair value of warrants issued to lender in conjunction with 2025 loan agreement (as defined in note 3) of $430K in Q4 2025.
- What does fair value of warrants issued to lender in conjunction with 2025 loan agreement (as defined in note 3) mean?
- This represents the fair value of equity warrants granted to lenders as a component of debt financing agreements, often serving as a 'sweetener' to reduce interest costs. While this does not involve an immediate cash outflow, it represents potential future dilution for shareholders and an increase in the effective cost of debt. Investors track this to evaluate the true economic cost of financing and the potential impact on future equity ownership.